ABLATE Study.

1. Women of age ≥ 30 and ≤ 50 years;

2. Pre-menopausal (absence of hot flashes);

3. Monthly menstrual cycles (cycle days 21-35) over the last 6 months;

4. Self-reported history of heavy menstrual bleeding as noted by flooding or interfering with work or social activities in 3 months of the past 6 months;

5. Documented history of excessive uterine bleeding defined by:

A. Alkaline hematin score of ≥ 160 mL for one month, within three months prior to the ablation procedure (this test may be repeated one time if the initial result is <160 mL and >120 mL); AND;

B. Previously failed, did not tolerate or refused medical therapy (oral contraceptive pills, NSAIDs, failed D&C or cyclic progestin therapy).

6. Evidence of normal PAP smear, including Class II/ASCUS that has been evaluated, within the last 6 months;

7. Evidence of normal endometrial biopsy results within the last 6 months;

8. Not currently using any hormonal contraceptives (for example, oral or injectable) and have not been using any hormonal contraceptives for a minimum of three months prior to study enrollment, and agree to not use any hormonal contraceptives from the time of study enrollment through the first 12 months following treatment, OR

Are currently using hormonal contraceptives, (for example, oral or injectable) and have been using hormonal contraceptives for a minimum of three months prior to study enrollment, and agree to continue to use hormonal contraceptives from the time of study enrollment through the first 12 months following treatment;

9. Are not currently taking any hormonal supplements (for example, estrogen) and have not been using any hormonal supplements for a minimum of three months prior to study enrollment and agree not to use hormonal supplements from the time of study enrollment through the first 12 months following treatment;

10. Do not desire current or future childbearing;

11. Not currently pregnant;

12. Do not desire to have an intrauterine device (IUD) placed or Essure or Adiana devices placed during the first 12 months following treatment
m);

13. Agrees to use sponsor provided sanitary pads and tampons during the conduct of the Alkaline Hematin tests;

14. Able and willing to comply with all study tests, procedures and assessment tools;

15. Able and willing to sign the Informed Consent Form;

16. Agrees to follow up period as outlined.

1. Hemoglobin < 4.65 mmol/L or considered by the investigator at risk for requiring blood transfusion within 12 months;

2. Known active pelvic inflammatory disease or genital tract infection (e.g., cervicitis, vaginitis, endometritis, salpingitis, or cystitis ), or active urinary tract infection;

3. Clotting defects or bleeding disorders (based on history) or on anti-coagulant therapy;

4. A patient with a history, known or suspected abdominal/pelvic cancer, endometrial carcinoma (uterine cancer) or unresolved potentially premalignant conditions such as complex endometrial hyperplasia;

5. Uterine length > 12 cm;

6. Submucosal myoma(s) > 4 cm diameter or that distort the uterine cavity;

7. Uterine and/or cervical polyps > 1 cm in diameter;

8. Intramural myomas that are > 4 cm in diameter or that distort the uterine cavity;

9. Bicornuate uterus;

10. Known or suspected hydrosalpinx;

11. Previous endometrial ablation procedure;

12. Desire for complete amenorrhea;

13. Known anatomical condition (e.g., history of previous classical cesarean section or transmural myomectomy, or uterine wall thickness < 1 cm) or pathologic condition that could lead to weakening of the myometrium;

14. Currently participating in another clinical trial;

15. The Investigator determines enrollment in the study is not appropriate for any reason.